Zurich, Switzerland
Procavea Biotech is a biotechnology startup based in Switzerland that aims to address the challenge of effectively delivering RNA-based drugs to non-liver tissues. Founded in 2021, the company is focused on developing nonviral protein cages as carriers for the delivery of RNA Therapeutics to specific tissues in the body.
It has recently received a significant boost with a Fr.150.00K grant investment from Venture Kick on 27 December 2023. This investment underscores the confidence of Venture Kick in the potential of Procavea Biotech's innovative approach to drug delivery, highlighting the promising future prospects of the company.
Procavea Biotech's mission, as encapsulated in their slogan, reflects the pressing need for improved methods of delivering RNA-based drugs, opening up possibilities for addressing a wide range of medical conditions. The progress and developments of this startup are certainly worth monitoring as they continue to make strides in the biotech and pharmaceutical landscape.
Overall, Procavea Biotech is positioned at the intersection of biotechnology and healthcare, with a clear vision and innovative approach that has captured the attention of Venture Kick and the potential to make a significant impact in the field of RNA therapeutics.
